It is no secret that vaccines are a hot space in biotech right now, and the 13th Annual BIO Investor Forum will feature several companies working on promising vaccine R&D. The event, scheduled for October 7-8 in San Francisco, Calif., will feature 120 late-stage private and emerging public company presentations.
Attendees at the BIO Investor Forum will hear from Immunovaccine, a clinical-stage vaccine development company focused on product candidates for cancer therapy, infectious disease and animal health. The company recently announced positive results from a Phase I/Ib clinical study of its lead cancer vaccine candidate showing early evidence of clinical activity in ovarian cancer patients.
Also presenting will be Vivaldi Biosciences Inc., a clinical-stage biotech company developing influenza vaccines that protect the most vulnerable populations – seniors and very young children. Vivaldi has completed four clinical trials, demonstrating preliminary safety and efficacy against five different influenza strains, including H5N1 or bird flu.
Another promising company presenting at the BIO Investor Forum is TheraVectys, a development-stage biotech company focused on the treatment and prevention of infectious diseases. Earlier this year, TheraVectys announced the finalization of patient recruitment for the first anti-HIV therapeutic vaccination trial to study the safety, tolerance and immunogenicity of its vaccine candidate in patients infected with HIV.
These three companies are just a handful of the exciting companies we’ll hear from at the event. Check out the full line up of presenting companies here, and register to join us at the upcoming BIO Investor Forum this fall.